WO2009088109A1 - Composition contenant de la diosgénine pour le blanchiment de la peau - Google Patents

Composition contenant de la diosgénine pour le blanchiment de la peau Download PDF

Info

Publication number
WO2009088109A1
WO2009088109A1 PCT/KR2008/000046 KR2008000046W WO2009088109A1 WO 2009088109 A1 WO2009088109 A1 WO 2009088109A1 KR 2008000046 W KR2008000046 W KR 2008000046W WO 2009088109 A1 WO2009088109 A1 WO 2009088109A1
Authority
WO
WIPO (PCT)
Prior art keywords
diosgenin
skin
composition
whitening
present
Prior art date
Application number
PCT/KR2008/000046
Other languages
English (en)
Inventor
Deok Hoon Park
Jong Sung Lee
Kwang Sun Jung
Chang Gu Hyun
Eunsun Jung
Original Assignee
Biospectrum, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biospectrum, Inc. filed Critical Biospectrum, Inc.
Priority to PCT/KR2008/000046 priority Critical patent/WO2009088109A1/fr
Priority to CN2008801260865A priority patent/CN101951880A/zh
Priority to JP2010519847A priority patent/JP2010535758A/ja
Publication of WO2009088109A1 publication Critical patent/WO2009088109A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a composition for skin whitening, and more particularly to a composition for skin whitening comprising diosgenin that has excellent stability without side effects on skin, and has a superior effect to inhibit pigmentation on skin by restraining melanin generation.
  • thiol based compounds such as glutathione and cysteine have unique unpleasant odors as well as problems in transdermal absorption, and glycosides and derivatives thereof have problems in that they cannot be appropriately used as mixed ingredients of cosmetics due to their high polarities.
  • Vitamin C is disadvantageous in that it is easily oxidized in an aqueous solution, so as not to continuously exhibit its effect.
  • skin- whitening compositions containing extracts of natural medicinal herbs have been developed. However, since most of them are colored, there are limitations in blending. Further, since their effective ingredients are not identified, consistent effects cannot be expected in products.
  • diosgenin is a plant-derived sapogenin, and reported to reduce arterial pressure and show preventive and therapeutic effect on cholesterin steatosis.
  • diosgenin is a plant-derived sapogenin, and reported to reduce arterial pressure and show preventive and therapeutic effect on cholesterin steatosis.
  • diosgenin as being usable in slimming compositions, on account of its ability to inhibit the storage of biochemical lipid material in adipose tissue.
  • WO 97/2504 disclosed is a composition containing diosgenin for the prevention or treatment of osteoporosis.
  • many studies have been made on the efficacy of a natural substance, diosgenin.
  • the present invention relates to a composition for whitening skin, comprising diosgenin.
  • Diosgenin ⁇ (3U,25R)-spirost-5-en-3- ⁇ f, of the present invention is a plant-derived sapogenin, represented by the following Ibrmula 1.
  • Ibrmula 1 a plant-derived sapogenin, represented by the following Ibrmula 1.
  • ChemistryRgure 1 [Chem.l]
  • Diosgenin of the present invention may be extracted and isolated from natural sources (e.g., D. japonica, D. tokoro, D. septemloba), prepared by chemical modification of saponins obtained from natural sources, or synthesized by chemical methods.
  • natural sources e.g., D. japonica, D. tokoro, D. septemloba
  • a commercially available diosgenin e.g., Diosgenin available from Sabinsa
  • diosgenin of the present invention may be extracted and isolated from plants such as D. japonica and D. tokoro using a solvent such as water, alcohol and acetone at 0 to 5O 0 C, which is well known to those skilled in the art.
  • diosgenin of the present invention In order to confirm the whitening effect of diosgenin of the present invention, its efficacy of suppressing melanin synthesis and tyrosinase activity was measured, which is a general screening method of whitening substances, and compared to that of a known skin whitening cosmetic material, vitamin C. As a result, diosgenin of the present invention exhibited excellent effects of suppressing melanin synthesis and tyrosinase activity, which was about 10% more than that of vitamin C at the same concentration. Thus, diosgenin of the present invention can be used for whitening skin.
  • diosgenin of Ibrmula 1 of the present invention includes derivatives that suppress melanin synthesis and/or tyrosinase activity to exhibit the effect of whitening skin, among its derivatives produced by addition or substitution of substituent.
  • the content of diosgenin may be preferably 0.0001 to 15 wt%, based on the total weight of the composition. If the content is less than 0.0001 wt%, the whitening effect is not sufficient, and if the content is more than 15 wt%, the whitening effect is slightly increased, whereas there is a problem in the stability upon formulation. More preferably, diosgenin is contained in an amount of 0.0001 to 10 wt%, based on the total weight of the composition. [21]
  • the present invention relates to a cosmetic composition for whitening skin, comprising the composition.
  • the cosmetic composition may include additives oommonly used in cosmetic formulations, for example, conventional auxiliary agents such as an antioxidant, a stabilizer, a solubilizing agent, a vitamin, a pigment, and a scent, and/or a carrier, in addition to diosgenin as an effective ingredient.
  • auxiliary agents such as an antioxidant, a stabilizer, a solubilizing agent, a vitamin, a pigment, and a scent, and/or a carrier, in addition to diosgenin as an effective ingredient.
  • the cosmetic composition may further include a skin absorption enhancer to improve skin- whitening effect.
  • the cosmetic composition of the present invention may be prepared as any formulation commonly prepared in the art.
  • the cosmetic composition may be formulated as, for example, a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powdered foundation, an emulsion foundation, a wax foundation, a spray, or the like, but not limited thereto.
  • the cosmetic composition may be prepared as a formulation such as a softening toner, a nutrient toner, a nutrient cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray, and a powder.
  • the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal oil, a vegetable oil, a wax, paraffin, a starch, traganth, a cellulose derivative, a polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, or the like may be used as the carrier ingredient.
  • the formulation of the cosmetic composition of the present invention is a powder or a spray
  • lactose, tal ⁇ silica, aluminum hydroxide, calcium silicate, or polyamide powders may be used as the carrier ingredient, and in particular, if the formulation is a spray, a propellent such as chlorofluorohydrocarbon, propane/butane and dimethyl ether may be used.
  • the formulation of the oosmetic composition of the present invention is a solution or an emulsion
  • a solvent, a solubilizing agent or an emulsifier may be used as the carrier ingredient, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan fatty acid esters.
  • the formulation of the cosmetic composition of the present invention is a suspension
  • a liquid diluent such as water, ethanol and propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and poly- oxyethylene sorbitan ester
  • macrocrystalline cellulose aluminum metahydroxide; bentonite; agar, traganth, or the like
  • bentonite agar, traganth, or the like
  • the formulation of the cosmetic composition of the present invention is a surfactant-containing cleanser, aliphatic aloohol sulfate, aliphatic aloohol ether sulfate, sulphosucdnic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetain, aliphatic alcohol, fatty add glyceride, fatty acid diethanolamide, vegetable oils, a lanolin derivative or ethoxylated glycerol fatty add ester, or the like may be used as the carrier ingredient.
  • the content of diosgenin may be 0.0001 to 15 wt%, and preferably 0.0001 to 10 wt%, based on the total weight of the cosmetic composition.
  • the present invention relates to a pharmaceutical composition for whitening skin, comprising the composition.
  • the content of diosgenin may be 0.0001 to 15 wt%, and preferably 0.0001 to 10 wt%, based on the total weight of the pharmaceutical composition.
  • the pharmaceutical composition of the present invention may further include suitable carriers, exdpients and diluents oommonly used in the preparation of pharmaceutical compositions.
  • the pharmaceutical composition of the present invention may be formulated into any suitable formulation including oral formulations such as powder, granule, tablet, capsule, suspension, emulsion, syrup and aerosol; external preparations such as ointment and cream; suppository, and sterilized solution for injection.
  • oral formulations such as powder, granule, tablet, capsule, suspension, emulsion, syrup and aerosol
  • external preparations such as ointment and cream
  • suppository suppository, and sterilized solution for injection.
  • composition according to the present invention may be administered to mammals such as rat, mouse, livestock, and human via various routes such as oral and parenteral routes (e.g., oral, rectal or intravenous, intramuscular, subcutaneous, intraepidural or intracerebrovascular injection), preferably transcutaneous route among parenteral routes, and more preferably topical application.
  • oral and parenteral routes e.g., oral, rectal or intravenous, intramuscular, subcutaneous, intraepidural or intracerebrovascular injection
  • transcutaneous route among parenteral routes preferably topical application.
  • An effective dosage of the present composition may be determined depending on the patient's age, gender, body weight, health state, and administration mode, lor topical administration, diosgenin may be preferably administered at a daily dosage of 1.0 to 3.0 mH one time or five times for 1 month or more.
  • diosgenin may be administered at a daily dosage of 0.1 to 100 mg/kg one time or several times, depending on the patient's age, gender, and body weight.
  • the dosage may be adjusted depending on administration route, severity of the disease, the patient's gender, body weight, and age.
  • the scope of the present invention is not limited to the dosage.
  • diosgenin was found to be safe for human skin as a natural substance. Accordingly, diosgenin of the present invention has no toxicity and side effects, thereby being safely used for a long period of time, in particular, applied to cosmetic and pharmaceutical compositions.
  • Murine B 16 melanoma cells were used to measure the inhibitory effect of diosgenin
  • Murine melanoma (B- 16 FlO) cells were inoculated on 6- well plates containing
  • DMEM media supplemented with 10% FBS (fetal bovine serum) (1 x 10 cells per well), and cultured in a 5% CO incubator at 37 0 C until reaching about 80% confluency. Then, media was removed from the cells, replaced with diluted fresh media, and cultured in a 5% CO incubator at 37 0 C for 3 days. The treatment concentration of diosgenin was determined over a range of 1 uM, 10 uM and 50 uM, which show no cytotoxicity. Media was removed from the cells, and the cells were washed with PBS (phosphate buffered saline), followed by trypsin treatment. The cells were recovered, and counted using a hemocytometer.
  • FBS fetal bovine serum
  • the cells were centrifuged at 5,000 to 10,000 rpm for 10 min, and the supernatant was removed to obtain a pellet.
  • the pellet was dried at 6O 0 C, and suspended in 100 ⁇ Jl of 1 M sodium hydroxide solution containing 10% DMSO in a 60 0 C water bath to obtain melanin in the cells.
  • Absorbance was determined at 4)0 nm using a microplate reader to assess the melanin content per cell. The results are shown in the following Table 1.
  • Murine B 16 melanoma cells were used to measure the inhibitory effect of diosgenin on tyrosinase activity, which was compared with the inhibitory effect of vitamin C on tyrosinase activity.
  • Murine melanoma (B- 16 Fl) cells were inoculated on 6- well plates containing DMEM media supplemented with 10% FBS (fetal bovine serum) (1 x 10 cells per well), and cultured in a 5% CO incubator at 37 0 C until reaching about 80% confluency. Then, media was removed from the cells, replaced with diluted fresh media, and cultured in a 5% CO incubator at 37 0 C for 3 days. The treatment concentration of diosgenin was determined over a range of 1 uM, 10 uM and 50 uM, which show no cytotoxicity. Media was removed from the cells, and the cells were washed with PBS (phosphate buffered saline), followed by trypsin treatment.
  • PBS phosphate buffered saline
  • the cells were recovered, and counted using a hemocytometer. Then, the cells were centrifuged at 5,000 to 10,000 rpm for 10 min, and the supernatant was removed to obtain a pellet. The pellet was resuspended using a lysis buffer, and centrifuged at 12,000 rpm for 10 min to collect the supernatant. Absorbance was determined at 492 nm using a microplate reader to assess the tyrosinase activity per cell. The results are shown in the following Table 2.
  • Example 3 Evaluation of skin whitening effect in animal [61] Brown guinea pigs (Tortoiseshell guinea pigs), which are known to increase pigmentation upon exposure to UV like human, were used to measure the whitening effect of diosgenin.
  • Example 4 Safety test of diosgenin on human skin [76] 4-1. External preparation containing diosgenin [77] In order to confirm the safety of diosgenin on human skin, external preparations containing diosgenin and vitamin C were prepared, and safety test of the external preparations was performed.
  • Skin external preparations containing diosgenin and vitamin C were prepared using the ingredients shown in Table 4 below. As a control group, a skin external preparation was prepared without a tyrosinase inhibitor.
  • the experimental groups 1 and 2 are skin external preparations containing diosgenin and vitamin C, respectively.
  • diosgenin exhibited higher inhibitory effects on tyrosinase activity and melanin synthesis than the known skin whitening agent, vitamin C. Further, diosgenin exhibits no cytotoxicity and skin complications, thereby being safely applied to cosmetic, pharmaceutical and food compositions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention porte sur une composition pour le blanchiment de la peau, caractérisée par le fait qu'elle comprend de la diosgénine comme principal élément actif. La composition comprenant la diosgénine peut être utilisée de façon sûre sans effet secondaire, et peut diminuer la synthèse de la mélanine pour inhiber la pigmentation, étant ainsi utilisée pour améliorer un mélasme ou des taches de rousseur, et blanchir la peau.
PCT/KR2008/000046 2008-01-04 2008-01-04 Composition contenant de la diosgénine pour le blanchiment de la peau WO2009088109A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/KR2008/000046 WO2009088109A1 (fr) 2008-01-04 2008-01-04 Composition contenant de la diosgénine pour le blanchiment de la peau
CN2008801260865A CN101951880A (zh) 2008-01-04 2008-01-04 包含薯蓣皂苷配基的皮肤增白组合物
JP2010519847A JP2010535758A (ja) 2008-01-04 2008-01-04 ジオスゲニンを含む皮膚美白用組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2008/000046 WO2009088109A1 (fr) 2008-01-04 2008-01-04 Composition contenant de la diosgénine pour le blanchiment de la peau

Publications (1)

Publication Number Publication Date
WO2009088109A1 true WO2009088109A1 (fr) 2009-07-16

Family

ID=40853215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/000046 WO2009088109A1 (fr) 2008-01-04 2008-01-04 Composition contenant de la diosgénine pour le blanchiment de la peau

Country Status (3)

Country Link
JP (1) JP2010535758A (fr)
CN (1) CN101951880A (fr)
WO (1) WO2009088109A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046645A (ja) * 2009-08-27 2011-03-10 Noevir Co Ltd 抗老化剤、抗酸化剤、美白剤、及び免疫賦活剤
JP2012020950A (ja) * 2010-07-13 2012-02-02 Kao Corp エンドセリン作用抑制剤及び美白剤
EP3127548A4 (fr) * 2014-03-31 2017-11-22 Amorepacific Corporation Composition comprenant un extrait d'essence d'absinthe alpine

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5718700B2 (ja) * 2011-03-29 2015-05-13 花王株式会社 新規セスタテルペン化合物、抗菌剤及び皮膚外用剤
JP5789339B2 (ja) 2013-01-21 2015-10-07 レジリオ株式会社 アルツハイマー病等を含む神経疾患の１，２５ｄ３−ｍａｒｒｓが関与する治療薬及び治療法
KR101713127B1 (ko) * 2014-05-13 2017-03-10 (주)케어젠 저색소증 개선 및 지방 형성 억제 효능을 갖는 펩타이드 및 이의 용도
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
KR101702441B1 (ko) * 2015-03-30 2017-02-06 (주)셀인바이오 피부 미백용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030152597A1 (en) * 2000-12-11 2003-08-14 Christel Liviero Use of at least one sapogenin for prevening the skin or ageing symptoms
US20040005370A1 (en) * 2000-07-13 2004-01-08 Lionel Breton Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof , and a metalloproteinase inhibitors
KR100782600B1 (ko) * 2006-09-12 2007-12-06 바이오스펙트럼 주식회사 디오스게닌 및 디오신을 포함하는 피부 노화 방지용 조성물
KR100795514B1 (ko) * 2006-07-06 2008-01-16 바이오스펙트럼 주식회사 디오스게닌을 함유하는 피부미백용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
JPH06219934A (ja) * 1992-11-26 1994-08-09 Dowa Mining Co Ltd 美白化粧料
JPH08133950A (ja) * 1994-11-07 1996-05-28 Shiseido Co Ltd 皮膚外用剤
JP2001019618A (ja) * 1999-07-06 2001-01-23 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
FR2799645B1 (fr) * 1999-10-13 2004-04-30 Oreal Utilisation de la dhea ou de ses precurseurs ou derives metaboliques comme depigmentant
FR2820320B1 (fr) * 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
FR2828100B1 (fr) * 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
FR2837704B1 (fr) * 2002-04-02 2005-01-14 Oreal Utilisation d'une sapogenine, ou un extrait naturel en contenant, pour le traitement des peaux seches oligoseborrheiques
JP2004352658A (ja) * 2003-05-29 2004-12-16 Shiseido Co Ltd 皮膚外用剤
JP2007274985A (ja) * 2006-04-07 2007-10-25 Takara Bio Inc トゲドコロ由来処理物を含有する食品

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005370A1 (en) * 2000-07-13 2004-01-08 Lionel Breton Composition, in particular cosmetic, containing dhea and/or a chemical or biological precursor or derivative thereof , and a metalloproteinase inhibitors
US20030152597A1 (en) * 2000-12-11 2003-08-14 Christel Liviero Use of at least one sapogenin for prevening the skin or ageing symptoms
KR100795514B1 (ko) * 2006-07-06 2008-01-16 바이오스펙트럼 주식회사 디오스게닌을 함유하는 피부미백용 조성물
KR100782600B1 (ko) * 2006-09-12 2007-12-06 바이오스펙트럼 주식회사 디오스게닌 및 디오신을 포함하는 피부 노화 방지용 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011046645A (ja) * 2009-08-27 2011-03-10 Noevir Co Ltd 抗老化剤、抗酸化剤、美白剤、及び免疫賦活剤
JP2012020950A (ja) * 2010-07-13 2012-02-02 Kao Corp エンドセリン作用抑制剤及び美白剤
EP3127548A4 (fr) * 2014-03-31 2017-11-22 Amorepacific Corporation Composition comprenant un extrait d'essence d'absinthe alpine

Also Published As

Publication number Publication date
CN101951880A (zh) 2011-01-19
JP2010535758A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
KR101823036B1 (ko) 멜라닌 색소 생성 억제제 및 이를 함유하는 화장료 조성물
WO2009088109A1 (fr) Composition contenant de la diosgénine pour le blanchiment de la peau
WO2004103265A2 (fr) Composition cosmetique de blanchiment et antioxydante renfermant du resveratrol et procede de preparation de celle-ci
US20100104524A1 (en) Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active
JP2019526602A (ja) マンノシルエリスリトール脂質を含む美白用組成物
US20170189326A1 (en) Topical Antiaging Polyphenol Compositions
JP2007210976A (ja) チロシナーゼ活性抑制剤及びこれを含む美白用化粧料
KR100795514B1 (ko) 디오스게닌을 함유하는 피부미백용 조성물
KR20220031274A (ko) 엘루테로사이드 e를 유효성분으로 함유하는 피부 미백용 화장료 조성물
WO2010115472A2 (fr) Composition topique pour l'éclaircissement de la peau
KR101245563B1 (ko) 마데카소사이드를 함유하는 피부 미백제
US20100061948A1 (en) Composition for skin whitening comprising artemisinine
KR101500551B1 (ko) 하이드록시시트릭산을 유효성분으로 함유하는 피부미백용 화장료 조성물
US9730872B2 (en) Method for improving skin conditions with veratric acid or acceptable salt thereof as an active ingredient
CN101854909B (zh) 含有桔梗皂苷-d的皮肤美白剂
KR100901519B1 (ko) 플라티코딘-디를 함유하는 피부미백제
KR102160306B1 (ko) 피부미백제
JPH08337534A (ja) メラニン生成抑制剤
KR101155695B1 (ko) 진센노사이드 알지3을 함유하는 피부미백용 조성물
KR20100013095A (ko) 안디로바 오일을 포함하는 화장료 조성물
KR100820575B1 (ko) 플라보노이드계 화합물을 포함하는 피부 미백용 조성물
KR0149791B1 (ko) 미백용 화장료 조성물
KR101768162B1 (ko) 미백 효능을 갖는 트리히드록시 이소플라본 및 상엽 추출물의 복합체
KR20140122012A (ko) 검은 생강 추출물을 포함하는 피부미백용 화장료 조성물
JP2009143893A (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有クレンジング化粧料

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126086.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704586

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010519847

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 08.11.2010

122 Ep: pct application non-entry in european phase

Ref document number: 08704586

Country of ref document: EP

Kind code of ref document: A1